A pilot study published in the New England Journal of Medicine suggests that a CRISPR-based drug may provide a permanent solution to lowering high cholesterol levels. The study, involving 15 patients, showed nearly a 50% reduction in low-density lipoprotein (LDL) and a 55% decrease in triglycerides, both linked to heart disease. Researchers aim to initiate Phase 2 and 3 clinical trials soon, targeting individuals with severe cholesterol issues. The goal is to develop a gene therapy that could offer lifelong protection against cardiovascular disease.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
